mRNA-3E10 Antibody Complex for Tissue Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current mRNA delivery methods for treating cardiac, hepatic, lung, and brain diseases face challenges such as limited ability of mRNA to cross cell membranes and susceptibility to degradation by extracellular ribonucleases.
Innovation Solution
Utilization of 3E10 antibodies or antigen-binding fragments thereof to form complexes with therapeutic mRNA molecules, which are then administered parenterally to efficiently deliver mRNA to cardiac, hepatic, lung, and neuronal tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mRNA is delivered using conventional liposomal-based delivery vehicles, then mRNA can be protected from degradation, but immunological challenges and complexity of production increase
Solution Approach 1:
The patent uses serum albumin as an intermediary carrier molecule to deliver mRNA. Albumin naturally binds mRNA through hydrophobic interactions and forms stable complexes that protect mRNA from ribonuclease degradation. This intermediary approach avoids the need for complex liposomal structures while leveraging the natural properties of albumin for stable, immunologically favorable delivery.
2Ease of manufacture
If mRNA is administered without a delivery vehicle, then production complexity is reduced, but mRNA cannot readily cross the cell membrane and is rapidly degraded
Solution Approach 1:
Serum albumin serves as a simple yet effective intermediary that bridges the gap between simple mRNA administration and complex delivery requirements. The albumin-mRNA complex forms through natural hydrophobic interactions, providing membrane-crossing capability and protection from degradation without requiring complex manufacturing processes.
Solution Approach 2:
The patent leverages the natural properties of serum albumin to perform multiple functions: protecting mRNA from degradation, facilitating cellular uptake, and enabling passive targeting to tissues. The albumin-mRNA complex self-assembles through hydrophobic interactions, eliminating the need for complex external delivery systems.
3Reliability
If higher molar ratios of albumin to mRNA are used, then mRNA protection from degradation is improved, but the quantity of substance required increases
Solution Approach 1:
The patent optimizes the albumin to mRNA molar ratio to achieve effective protection with minimal albumin用量. By carefully controlling this parameter, the formulation achieves maximum protective effect while minimizing the quantity of albumin required, balancing stability with dosage efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of 3E10 antibodies or antigen-binding fragments enhances the protection and delivery of mRNA, improving its pharmacokinetic properties and enabling effective treatment of the mentioned diseases.
Implementation Method 1
a non-covalent complex formed between a therapeutic mRNA polynucleotide, and a 3E10 antibody or antigen binding fragment thereof
Data Source
AI summary
Compositions and methods are provided for treating diseases and disorders, e.g., cardiac muscle, hepatic, lung, and brain, by administering a complex formed between a therapeutic mRNA polynucleotide and a 3E10 antibody or antigen binding fragment thereof. In some instances, the complexes are stabilized through a molar ratio of 3E10 antibody or antigen binding fragment thereof to therapeutic polynucleotide of at least about 2:1.